Myeloprotection
Showing 1 - 4 of 4
Extensive-stage Small-cell Lung Cancer Trial (Trilaciclib, Placebo, Topotecan)
Not yet recruiting
- Extensive-stage Small-cell Lung Cancer
- Trilaciclib
- +2 more
- (no location specified)
May 22, 2023
Triple Negative Breast Cancer, Breast Cancer Trial in United States (Trilaciclib, Cylophosphamide, Doxorubicin)
Active, not recruiting
- Triple Negative Breast Cancer
- Breast Cancer
- Trilaciclib
- +5 more
-
Los Alamitos, California
- +6 more
Jan 25, 2023
TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial in Worldwide (Trilaciclib, Placebo, Gemcitabine)
Active, not recruiting
- TNBC - Triple-Negative Breast Cancer
- Breast Cancer
- Trilaciclib
- +3 more
-
Birmingham, Alabama
- +111 more
Oct 25, 2022
Metastatic NSCLC, NSCLC, Lung Cancer Trial in United States (Trilaciclib, Placebo, Docetaxel)
Terminated
- Metastatic Non-Small Cell Lung Cancer
- +2 more
- Trilaciclib
- +2 more
-
Phoenix, Arizona
- +11 more
Feb 11, 2022